Kaneka（KKA）株式概要株式会社カネカは、ポリ塩化ビニル（PVC）、架橋PVC、PVC-PVAcポリマー、ペーストPVC、アクリルグラフト塩化ビニル共重合体、塩素化PVCの製造・販売を国内外で行っています。 詳細KKA ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長1/6過去の実績4/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より10.6%で取引されている 収益は年間2.61%増加すると予測されています 過去1年間で収益は22.4%増加しました 同業他社や業界と比較して、良好な取引価格 リスク分析財務結果に影響を与える大きな一時的項目 2.9%の配当はフリーキャッシュフローで十分にカバーされていない すべてのリスクチェックを見るKKA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€29.407.3% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture0916b2016201920222025202620282031Revenue JP¥915.9bEarnings JP¥35.0bAdvancedSet Fair ValueView all narrativesKaneka Corporation 競合他社FuchsSymbol: XTRA:FPE3Market cap: €4.7bSIMONASymbol: DB:SIM0Market cap: €339.0mAlzChem GroupSymbol: XTRA:ACTMarket cap: €1.9bEvonik IndustriesSymbol: XTRA:EVKMarket cap: €7.8b価格と性能株価の高値、安値、推移の概要Kaneka過去の株価現在の株価JP¥29.4052週高値JP¥29.4052週安値JP¥21.40ベータ0.311ヶ月の変化18.55%3ヶ月変化11.36%1年変化30.09%3年間の変化18.55%5年間の変化-10.91%IPOからの変化15.91%最新ニュースReported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.最新情報をもっと見るRecent updatesReported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.お知らせ • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.お知らせ • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025お知らせ • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025お知らせ • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.お知らせ • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025お知らせ • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.お知らせ • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: JP¥49.73 (vs JP¥71.73 in 2Q 2024)Second quarter 2025 results: EPS: JP¥49.73 (down from JP¥71.73 in 2Q 2024). Revenue: JP¥197.6b (up 5.4% from 2Q 2024). Net income: JP¥3.13b (down 33% from 2Q 2024). Profit margin: 1.6% (down from 2.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year.Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years.Upcoming Dividend • Sep 20Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 05 December 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%).お知らせ • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €20.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €16.18 per share.お知らせ • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥358 (vs JP¥350 in FY 2023)Full year 2024 results: EPS: JP¥358 (up from JP¥350 in FY 2023). Revenue: JP¥762.3b (flat on FY 2023). Net income: JP¥23.2b (flat on FY 2023). Profit margin: 3.0% (in line with FY 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.お知らせ • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.Upcoming Dividend • Mar 21Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.8%).お知らせ • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥69.95 (vs JP¥34.88 in 3Q 2023)Third quarter 2024 results: EPS: JP¥69.95 (up from JP¥34.88 in 3Q 2023). Revenue: JP¥194.6b (up 4.3% from 3Q 2023). Net income: JP¥4.54b (up 96% from 3Q 2023). Profit margin: 2.3% (up from 1.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.Buying Opportunity • Jan 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 7.0%. Revenue is forecast to grow by 8.9% in 2 years. Earnings is forecast to grow by 92% in the next 2 years.お知らせ • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥71.73 (vs JP¥91.80 in 2Q 2023)Second quarter 2024 results: EPS: JP¥71.73 (down from JP¥91.80 in 2Q 2023). Revenue: JP¥187.4b (flat on 2Q 2023). Net income: JP¥4.66b (down 23% from 2Q 2023). Profit margin: 2.5% (down from 3.2% in 2Q 2023). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 21Upcoming dividend of JP¥55.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 43% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%).お知らせ • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023New Risk • Aug 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.2% net profit margin).Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: JP¥65.35 (vs JP¥161 in 1Q 2023)First quarter 2024 results: EPS: JP¥65.35 (down from JP¥161 in 1Q 2023). Revenue: JP¥182.7b (down 5.2% from 1Q 2023). Net income: JP¥4.24b (down 60% from 1Q 2023). Profit margin: 2.3% (down from 5.5% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023Reported Earnings • May 18Full year 2023 earnings released: EPS: JP¥350 (vs JP¥406 in FY 2022)Full year 2023 results: EPS: JP¥350 (down from JP¥406 in FY 2022). Revenue: JP¥755.8b (up 9.3% from FY 2022). Net income: JP¥23.0b (down 13% from FY 2022). Profit margin: 3.0% (down from 3.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.お知らせ • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.Upcoming Dividend • Mar 23Upcoming dividend of JP¥55.00 per share at 3.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 13 June 2023. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%).Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥34.87 (vs JP¥111 in 3Q 2022)Third quarter 2023 results: EPS: JP¥34.87 (down from JP¥111 in 3Q 2022). Revenue: JP¥186.5b (up 4.5% from 3Q 2022). Net income: JP¥2.32b (down 68% from 3Q 2022). Profit margin: 1.2% (down from 4.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.お知らせ • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Yuko Sasakawa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥91.80 (vs JP¥107 in 2Q 2022)Second quarter 2023 results: EPS: JP¥91.80 (down from JP¥107 in 2Q 2022). Revenue: JP¥187.9b (up 13% from 2Q 2022). Net income: JP¥6.05b (down 14% from 2Q 2022). Profit margin: 3.2% (down from 4.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.Upcoming Dividend • Sep 22Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%).お知らせ • Sep 10+ 1 more updateKaneka Corporation (TSE:4118) announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 2,300,000 shares, representing 3.42% of the outstanding shares for ¥10,000 million. The purpose of the program is to improve shareholder value and to implement a flexible capital policy in response to changes in the business environment. The program will run until March 24, 2022. As of August 31, 2022, the company had 67,195,241 shares outstanding and 804,759 shares in treasury.Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥161 (vs JP¥119 in 1Q 2022)First quarter 2023 results: EPS: JP¥161 (up from JP¥119 in 1Q 2022). Revenue: JP¥192.7b (up 17% from 1Q 2022). Net income: JP¥10.5b (up 36% from 1Q 2022). Profit margin: 5.5% (up from 4.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.2%, compared to a 2.9% growth forecast for the industry in Germany.お知らせ • Jun 11Kaneka Corporation to Report Q1, 2023 Results on Aug 10, 2022Kaneka Corporation announced that they will report Q1, 2023 results on Aug 10, 2022Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥406 (vs JP¥243 in FY 2021)Full year 2022 results: EPS: JP¥406 (up from JP¥243 in FY 2021). Revenue: JP¥691.5b (up 20% from FY 2021). Net income: JP¥26.5b (up 67% from FY 2021). Profit margin: 3.8% (up from 2.7% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 6.4% growth forecast for the industry in Germany.お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 29, 2022Kaneka Corporation, Annual General Meeting, Jun 29, 2022.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Managing Executive Officer & Director Katsunobu Doro was the last director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Buying Opportunity • Apr 21Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €31.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 9.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings is also forecast to grow by 6.8% per annum over the same time period.お知らせ • Apr 13Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) VariantsKaneka Corporation released KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. This is expected to help reduce the burden placed by testing and to assist with selecting the best suitable drugs and treatment approaches for each variant in clinical settings. Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta)” which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples.Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (4.7%).Reported Earnings • Feb 09Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥111 (up from JP¥110 in 3Q 2021). Revenue: JP¥178.4b (up 15% from 3Q 2021). Net income: JP¥7.26b (up 1.0% from 3Q 2021). Profit margin: 4.1% (down from 4.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is forecast to stay flat compared to a 6.0% growth forecast for the industry in Germany.Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥107 (vs JP¥31.26 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥166.2b (up 19% from 2Q 2021). Net income: JP¥7.01b (up 244% from 2Q 2021). Profit margin: 4.2% (up from 1.5% in 2Q 2021). The increase in margin was driven by higher revenue.Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.7%).Reported Earnings • Aug 14First quarter 2022 earnings released: EPS JP¥119 (vs JP¥6.70 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥164.1b (up 30% from 1Q 2021). Net income: JP¥7.76b (up JP¥7.32b from 1Q 2021). Profit margin: 4.7% (up from 0.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥243 (vs JP¥215 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥577.4b (down 4.0% from FY 2020). Net income: JP¥15.8b (up 13% from FY 2020). Profit margin: 2.7% (up from 2.3% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Mar 24Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.6%).Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥39.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Chemicals industry in Germany. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €24.18 per share.お知らせ • Mar 11Kaneka Corporation to Report Fiscal Year 2021 Results on May 13, 2021Kaneka Corporation announced that they will report fiscal year 2021 results on May 13, 2021Is New 90 Day High Low • Feb 16New 90-day high: €32.60The company is up 29% from its price of €25.20 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.16 per share.Reported Earnings • Feb 11Third quarter 2021 earnings released: EPS JP¥110 (vs JP¥48.85 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥154.8b (up 1.4% from 3Q 2020). Net income: JP¥7.18b (up 125% from 3Q 2020). Profit margin: 4.6% (up from 2.1% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Analyst Estimate Surprise Post Earnings • Feb 11Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.3%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Jan 26New 90-day high: €30.00The company is up 26% from its price of €23.80 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.58 per share.Is New 90 Day High Low • Jan 08New 90-day high: €29.20The company is up 16% from its price of €25.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.44 per share.お知らせ • Dec 17Kaneka Corporation to Report Q3, 2021 Results on Feb 09, 2021Kaneka Corporation announced that they will report Q3, 2021 results on Feb 09, 2021Is New 90 Day High Low • Dec 17New 90-day high: €28.40The company is up 19% from its price of €23.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.62 per share.Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 1.1%, compared to a 3.6% growth forecast for the Chemicals industry in Germany.Is New 90 Day High Low • Nov 12New 90-day high: €25.80The company is up 22% from its price of €21.20 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.41 per share.Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥31.26The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥140.1b (down 7.3% from 2Q 2020). Net income: JP¥2.04b (down 20% from 2Q 2020). Profit margin: 1.5% (down from 1.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Oct 12New 90-day high: €25.60The company is up 21% from its price of €21.20 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.76 per share.Is New 90 Day High Low • Sep 18New 90-day high: €24.80The company is up 8.0% from its price of €23.00 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.11 per share.お知らせ • Sep 13Kaneka Corporation to Report Q2, 2021 Results on Nov 10, 2020Kaneka Corporation announced that they will report Q2, 2021 results on Nov 10, 2020お知らせ • Jun 28Kaneka Corporation to Report Q1, 2021 Results on Aug 12, 2020Kaneka Corporation announced that they will report Q1, 2021 results on Aug 12, 2020株主還元KKADE ChemicalsDE 市場7D2.1%-0.8%0.7%1Y30.1%3.8%2.0%株主還元を見る業界別リターン: KKA過去 1 年間で3.8 % の収益を上げたGerman Chemicals業界を上回りました。リターン対市場: KKA過去 1 年間で2 % の収益を上げたGerman市場を上回りました。価格変動Is KKA's price volatile compared to industry and market?KKA volatilityKKA Average Weekly Movement5.4%Chemicals Industry Average Movement5.7%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: KKA 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: KKAの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト194911,512Kazuhiko Fujiiwww.kaneka.co.jp株式会社カネカは、ポリ塩化ビニル（PVC）、架橋PVC、PVC-PVAcポリマー、ペーストPVC、アクリルグラフト塩化ビニル共重合体、塩素化PVCの製造・販売を国内外で行っています。衝撃改良剤、加工助剤、特殊添加剤、熱硬化性樹脂用強靭剤、シリル末端ポリエーテル、アクリルシリコン、末端反応性液状アクリル、生分解性ポリマー、射出成形用エンジニアリング樹脂、アクリルフィルム、イソブチレン系熱可塑性エラストマー製品などを提供している。また、ポリプロピレンフォーム、カネライトフォーム、押出発泡ポリスチレン断熱材、ポリイミドフィルム、光学用透明フィルム、高熱伝導性グラファイトシート、多層断熱材、透明導電性フィルム、耐熱・耐光性透明樹脂製品も提供している。また、住宅用・公共用・産業用の太陽光発電システム、エコファー、難燃剤、ヘアアクセサリー、新素材、有機EL照明パネル、リチウムイオン電池、バイオサーファクタントを提供している。また、インターベンション、血液浄化、消化器インターベンション、検査機器、再生医療・細胞治療、遺伝子診断関連製品、低分子医薬材料、モノクローナル抗体精製用アフィニティークロマトグラフィー樹脂、バイオ医薬品、経皮吸収型医薬品、衝撃吸収パッド付きインナーウェアなどを提供している。さらに、乳製品、ヨーグルト、マーガリン、油脂、ホイップクリーム、フィリング、パン酵母・生地改良剤、加工果実、バター、ショートニング、カカオバター代替品、練り込み用クリーム、冷凍生地、香辛料、不凍材料、および補酵素、プロバイオティクス、栄養成分、肥料を含む医薬品・サプリメント栄養ソリューションも提供している。カネカは1949年に設立され、東京に本社を置く。もっと見るKaneka Corporation 基礎のまとめKaneka の収益と売上を時価総額と比較するとどうか。KKA 基礎統計学時価総額€1.70b収益（TTM）€166.73m売上高(TTM)€4.37b10.2xPER（株価収益率0.4xP/SレシオKKA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計KKA 損益計算書（TTM）収益JP¥811.64b売上原価JP¥586.09b売上総利益JP¥225.55bその他の費用JP¥194.57b収益JP¥30.98b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）541.31グロス・マージン27.79%純利益率3.82%有利子負債／自己資本比率40.9%KKA の長期的なパフォーマンスは？過去の実績と比較を見る配当金2.9%現在の配当利回り36%配当性向KKA 配当は確実ですか？KKA 配当履歴とベンチマークを見るKKA 、いつまでに購入すれば配当金を受け取れますか？Kaneka 配当日配当落ち日Mar 30 2026配当支払日Jun 05 2026配当落ちまでの日数62 days配当支払日までの日数5 daysKKA 配当は確実ですか？KKA 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/31 07:24終値2026/05/29 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kaneka Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16 アナリスト機関Kyoji ChibaBofA Global ResearchTakao KanaiCitigroup IncKeita IkedaDaiwa Securities Co. Ltd.13 その他のアナリストを表示
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026
お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026
お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.
Reported Earnings • May 20Full year 2026 earnings released: EPS: JP¥501 (vs JP¥401 in FY 2025)Full year 2026 results: EPS: JP¥501 (up from JP¥401 in FY 2025). Revenue: JP¥811.6b (flat on FY 2025). Net income: JP¥31.0b (up 22% from FY 2025). Profit margin: 3.8% (up from 3.1% in FY 2025). Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Independent Director Hiromi Miyake was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 14+ 1 more updateKaneka Corporation, Annual General Meeting, Jun 26, 2026Kaneka Corporation, Annual General Meeting, Jun 26, 2026.
お知らせ • Mar 18Kaneka Corporation to Report Fiscal Year 2026 Results on May 14, 2026Kaneka Corporation announced that they will report fiscal year 2026 results on May 14, 2026
お知らせ • Dec 02Kaneka Corporation to Report Q3, 2026 Results on Feb 10, 2026Kaneka Corporation announced that they will report Q3, 2026 results on Feb 10, 2026
お知らせ • Nov 12+ 1 more updateKaneka Corporation Revises Consolidated Earnings Guidance for the Fiscal Year from April 1, 2025 to March 31, 2026Kaneka Corporation revised consolidated earnings guidance for the fiscal year from April 1, 2025 to March 31, 2026. For the year, the company expects net sales of ¥800,000 million compared to previous guidance of ¥820,000 million, operating income of ¥37,000 million compared to previous guidance of ¥42,000 million, net income attributable to owners of parent of ¥33,000 million compared to previous guidance of ¥33,000 million and net income per share of ¥534.03 compared to previous guidance of ¥524.36.
お知らせ • Nov 10Kaneka Expands Global Reach with i-ED COIL Launch in EuropeKaneka Corporation has begun sales of its i-ED COIL, a brain aneurysm embolization coil in Europe as of October. The product obtained EC certification under an EU Medical Device Regulation in July and will be distributed primarily in Europe through Kaneka Medical Europe N.V. The i-ED COIL provides world-class flexibility, enabled by its specialized wire thickness and structural features. This flexibility enables coils to be packed more densely within aneurysms than conventional products and allows treatment of aneurysms with irregular shapes. Its role in reducing the risk of aneurysm rupture is highly regarded by physicians, and since its launch in the Japanese market in 2019, sales have continued to grow steadily. Kaneka is expanding its business in a wide range of fields, which include devices for the treatment of cardiac, peripheral vascular, and cerebrovascular diseases, as well as medical devices used in the treatment of gastrointestinal tract diseases. Looking ahead, company aim to strengthen the global reach of products such as i-ED COIL and achieve sales of JPY 300 billion by 2030 in the Health Care Solution Unit including these medical businesses.
お知らせ • Sep 01Kaneka Corporation to Report Q2, 2026 Results on Nov 12, 2025Kaneka Corporation announced that they will report Q2, 2026 results on Nov 12, 2025
お知らせ • Jun 13Kaneka Corporation to Report Q1, 2026 Results on Aug 08, 2025Kaneka Corporation announced that they will report Q1, 2026 results on Aug 08, 2025
お知らせ • May 16Kaneka Corporation (TSE:4118) announces an Equity Buyback for 3,000,000 shares, representing 4.77% for ¥12,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 3,000,000 shares, representing 4.77% of the outstanding shares for ¥12,000 million. The purpose of the program is to improve shareholder value and implement flexible capital policies in response to changes in the business environment. The program will run until March 29, 2026. As of April 30, 2025, the company had 62,934,292 shares outstanding and 3,065,708 shares in treasury.
お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 27, 2025Kaneka Corporation, Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 21Kaneka Corporation to Report Fiscal Year 2025 Results on May 14, 2025Kaneka Corporation announced that they will report fiscal year 2025 results on May 14, 2025
お知らせ • Jan 09Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd.Kaneka Corporation (TSE:4118) acquired 96.80% stake in EndoStream Medical Ltd on December 23, 2024. By combining Kaneka's manufacturing and ESM's technology, we will jointly develop new medical devices, mainly for cerebrovascular treatment, in addition to the Nautilus device for aneurysm treatment currently under development. We aim to achieve sales of over ¥20 billion by 2030. Kaneka Corporation (TSE:4118) completed the acquisition of 96.80% stake in EndoStream Medical Ltd on December 23, 2024.
お知らせ • Dec 21Kaneka Corporation to Report Q3, 2025 Results on Feb 13, 2025Kaneka Corporation announced that they will report Q3, 2025 results on Feb 13, 2025
Reported Earnings • Nov 15Second quarter 2025 earnings released: EPS: JP¥49.73 (vs JP¥71.73 in 2Q 2024)Second quarter 2025 results: EPS: JP¥49.73 (down from JP¥71.73 in 2Q 2024). Revenue: JP¥197.6b (up 5.4% from 2Q 2024). Net income: JP¥3.13b (down 33% from 2Q 2024). Profit margin: 1.6% (down from 2.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 15% per year.
Valuation Update With 7 Day Price Move • Nov 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 11x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years.
Upcoming Dividend • Sep 20Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 27 September 2024. Payment date: 05 December 2024. Payout ratio is a comfortable 27% but the company is not cash flow positive. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.0%).
お知らせ • Sep 18Kaneka Corporation to Report Q2, 2025 Results on Nov 12, 2024Kaneka Corporation announced that they will report Q2, 2025 results on Nov 12, 2024
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €20.80, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 12x in the Chemicals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €16.18 per share.
お知らせ • Jun 18Kaneka Corporation to Report Q1, 2025 Results on Aug 08, 2024Kaneka Corporation announced that they will report Q1, 2025 results on Aug 08, 2024
Reported Earnings • May 19Full year 2024 earnings released: EPS: JP¥358 (vs JP¥350 in FY 2023)Full year 2024 results: EPS: JP¥358 (up from JP¥350 in FY 2023). Revenue: JP¥762.3b (flat on FY 2023). Net income: JP¥23.2b (flat on FY 2023). Profit margin: 3.0% (in line with FY 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 2 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 11% per year.
お知らせ • May 16Kaneka Corporation, Annual General Meeting, Jun 27, 2024Kaneka Corporation, Annual General Meeting, Jun 27, 2024.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 12 June 2024. Payout ratio is a comfortable 41% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (4.8%).
お知らせ • Mar 13Kaneka Corporation to Report Fiscal Year 2024 Results on May 14, 2024Kaneka Corporation announced that they will report fiscal year 2024 results on May 14, 2024
Reported Earnings • Feb 11Third quarter 2024 earnings released: EPS: JP¥69.95 (vs JP¥34.88 in 3Q 2023)Third quarter 2024 results: EPS: JP¥69.95 (up from JP¥34.88 in 3Q 2023). Revenue: JP¥194.6b (up 4.3% from 3Q 2023). Net income: JP¥4.54b (up 96% from 3Q 2023). Profit margin: 2.3% (up from 1.2% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • Jan 18Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 5.2%. The fair value is estimated to be €27.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 7.0%. Revenue is forecast to grow by 8.9% in 2 years. Earnings is forecast to grow by 92% in the next 2 years.
お知らせ • Nov 30Kaneka Corporation to Report Q3, 2024 Results on Feb 08, 2024Kaneka Corporation announced that they will report Q3, 2024 results on Feb 08, 2024
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥71.73 (vs JP¥91.80 in 2Q 2023)Second quarter 2024 results: EPS: JP¥71.73 (down from JP¥91.80 in 2Q 2023). Revenue: JP¥187.4b (flat on 2Q 2023). Net income: JP¥4.66b (down 23% from 2Q 2023). Profit margin: 2.5% (down from 3.2% in 2Q 2023). Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 21Upcoming dividend of JP¥55.00 per share at 2.7% yieldEligible shareholders must have bought the stock before 28 September 2023. Payment date: 05 December 2023. Payout ratio is a comfortable 43% but the company is not cash flow positive. Trailing yield: 2.7%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (5.9%).
お知らせ • Sep 13Kaneka Corporation to Report Q2, 2024 Results on Nov 09, 2023Kaneka Corporation announced that they will report Q2, 2024 results on Nov 09, 2023
New Risk • Aug 10New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 4.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (2.2% net profit margin).
Reported Earnings • Aug 10First quarter 2024 earnings released: EPS: JP¥65.35 (vs JP¥161 in 1Q 2023)First quarter 2024 results: EPS: JP¥65.35 (down from JP¥161 in 1Q 2023). Revenue: JP¥182.7b (down 5.2% from 1Q 2023). Net income: JP¥4.24b (down 60% from 1Q 2023). Profit margin: 2.3% (down from 5.5% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 15Kaneka Corporation to Report Q1, 2024 Results on Aug 09, 2023Kaneka Corporation announced that they will report Q1, 2024 results on Aug 09, 2023
Reported Earnings • May 18Full year 2023 earnings released: EPS: JP¥350 (vs JP¥406 in FY 2022)Full year 2023 results: EPS: JP¥350 (down from JP¥406 in FY 2022). Revenue: JP¥755.8b (up 9.3% from FY 2022). Net income: JP¥23.0b (down 13% from FY 2022). Profit margin: 3.0% (down from 3.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.1% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
お知らせ • May 17Kaneka Corporation, Annual General Meeting, Jun 29, 2023Kaneka Corporation, Annual General Meeting, Jun 29, 2023.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥55.00 per share at 3.3% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 13 June 2023. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 3.3%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.7%).
Reported Earnings • Feb 12Third quarter 2023 earnings released: EPS: JP¥34.87 (vs JP¥111 in 3Q 2022)Third quarter 2023 results: EPS: JP¥34.87 (down from JP¥111 in 3Q 2022). Revenue: JP¥186.5b (up 4.5% from 3Q 2022). Net income: JP¥2.32b (down 68% from 3Q 2022). Profit margin: 1.2% (down from 4.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 1.8% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
お知らせ • Dec 17Kaneka Corporation to Report Q3, 2023 Results on Feb 08, 2023Kaneka Corporation announced that they will report Q3, 2023 results on Feb 08, 2023
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 9 experienced directors. 2 highly experienced directors. 4 independent directors (8 non-independent directors). Independent Director Yuko Sasakawa was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: JP¥91.80 (vs JP¥107 in 2Q 2022)Second quarter 2023 results: EPS: JP¥91.80 (down from JP¥107 in 2Q 2022). Revenue: JP¥187.9b (up 13% from 2Q 2022). Net income: JP¥6.05b (down 14% from 2Q 2022). Profit margin: 3.2% (down from 4.2% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥55.00 per shareEligible shareholders must have bought the stock before 29 September 2022. Payment date: 06 December 2022. Payout ratio is a comfortable 25% but the company is not cash flow positive. Trailing yield: 2.9%. Lower than top quartile of German dividend payers (5.1%). Lower than average of industry peers (6.1%).
お知らせ • Sep 10+ 1 more updateKaneka Corporation (TSE:4118) announces an Equity Buyback for 2,300,000 shares, representing 3.42% for ¥10,000 million.Kaneka Corporation (TSE:4118) announces a share repurchase program. Under the program, the company will repurchase 2,300,000 shares, representing 3.42% of the outstanding shares for ¥10,000 million. The purpose of the program is to improve shareholder value and to implement a flexible capital policy in response to changes in the business environment. The program will run until March 24, 2022. As of August 31, 2022, the company had 67,195,241 shares outstanding and 804,759 shares in treasury.
Reported Earnings • Aug 12First quarter 2023 earnings released: EPS: JP¥161 (vs JP¥119 in 1Q 2022)First quarter 2023 results: EPS: JP¥161 (up from JP¥119 in 1Q 2022). Revenue: JP¥192.7b (up 17% from 1Q 2022). Net income: JP¥10.5b (up 36% from 1Q 2022). Profit margin: 5.5% (up from 4.7% in 1Q 2022). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 3.2%, compared to a 2.9% growth forecast for the industry in Germany.
お知らせ • Jun 11Kaneka Corporation to Report Q1, 2023 Results on Aug 10, 2022Kaneka Corporation announced that they will report Q1, 2023 results on Aug 10, 2022
Reported Earnings • May 15Full year 2022 earnings released: EPS: JP¥406 (vs JP¥243 in FY 2021)Full year 2022 results: EPS: JP¥406 (up from JP¥243 in FY 2021). Revenue: JP¥691.5b (up 20% from FY 2021). Net income: JP¥26.5b (up 67% from FY 2021). Profit margin: 3.8% (up from 2.7% in FY 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 7.3%, compared to a 6.4% growth forecast for the industry in Germany.
お知らせ • May 14Kaneka Corporation, Annual General Meeting, Jun 29, 2022Kaneka Corporation, Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 4 independent directors on the board. The company's board is composed of: 4 independent directors. 8 non-independent directors. Managing Executive Officer & Director Katsunobu Doro was the last director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Apr 21Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 14%. The fair value is estimated to be €31.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 9.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings is also forecast to grow by 6.8% per annum over the same time period.
お知らせ • Apr 13Kaneka Launches New PCR Test Kit for Identifying the COVID-19 Omicron (BA.1) and "Stealth" Omicron (BA.2) VariantsKaneka Corporation released KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta) ver.2”, a real-time PCR test kit capable of simultaneously detecting the Omicron (BA.1), "Stealth" Omicron (BA.2), and Delta variants of COVID-19. This test kit uses a proprietary reagent developed using Kaneka's molecular testing-related technologies to detect the presence of three variants with a single PCR test. This is expected to help reduce the burden placed by testing and to assist with selecting the best suitable drugs and treatment approaches for each variant in clinical settings. Kaneka has already released the KANEKA Direct RT-PCR Kit SARS-CoV-2, an in-vitro diagnostic reagent that uses Kaneka's original sample processing technology to produce test results in less than an hour, KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta)” which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥60.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 06 June 2022. Payout ratio is a comfortable 23% and this is well supported by cash flows. Trailing yield: 3.4%. Lower than top quartile of German dividend payers (3.6%). Lower than average of industry peers (4.7%).
Reported Earnings • Feb 09Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: EPS: JP¥111 (up from JP¥110 in 3Q 2021). Revenue: JP¥178.4b (up 15% from 3Q 2021). Net income: JP¥7.26b (up 1.0% from 3Q 2021). Profit margin: 4.1% (down from 4.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 4.9%. Over the next year, revenue is forecast to stay flat compared to a 6.0% growth forecast for the industry in Germany.
Reported Earnings • Nov 10Second quarter 2022 earnings released: EPS JP¥107 (vs JP¥31.26 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥166.2b (up 19% from 2Q 2021). Net income: JP¥7.01b (up 244% from 2Q 2021). Profit margin: 4.2% (up from 1.5% in 2Q 2021). The increase in margin was driven by higher revenue.
Upcoming Dividend • Sep 22Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 29 September 2021. Payment date: 07 December 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (3.7%).
Reported Earnings • Aug 14First quarter 2022 earnings released: EPS JP¥119 (vs JP¥6.70 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥164.1b (up 30% from 1Q 2021). Net income: JP¥7.76b (up JP¥7.32b from 1Q 2021). Profit margin: 4.7% (up from 0.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥243 (vs JP¥215 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥577.4b (down 4.0% from FY 2020). Net income: JP¥15.8b (up 13% from FY 2020). Profit margin: 2.7% (up from 2.3% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Mar 24Upcoming dividend of JP¥50.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 11 June 2021. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (3.6%).
Valuation Update With 7 Day Price Move • Mar 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to JP¥39.40, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 19x in the Chemicals industry in Germany. Total returns to shareholders of 8.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €24.18 per share.
お知らせ • Mar 11Kaneka Corporation to Report Fiscal Year 2021 Results on May 13, 2021Kaneka Corporation announced that they will report fiscal year 2021 results on May 13, 2021
Is New 90 Day High Low • Feb 16New 90-day high: €32.60The company is up 29% from its price of €25.20 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €19.16 per share.
Reported Earnings • Feb 11Third quarter 2021 earnings released: EPS JP¥110 (vs JP¥48.85 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥154.8b (up 1.4% from 3Q 2020). Net income: JP¥7.18b (up 125% from 3Q 2020). Profit margin: 4.6% (up from 2.1% in 3Q 2020). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Analyst Estimate Surprise Post Earnings • Feb 11Revenue beats expectationsRevenue exceeded analyst estimates by 4.7%. Over the next year, revenue is forecast to grow 3.3%, compared to a 5.1% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Jan 26New 90-day high: €30.00The company is up 26% from its price of €23.80 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.58 per share.
Is New 90 Day High Low • Jan 08New 90-day high: €29.20The company is up 16% from its price of €25.20 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.44 per share.
お知らせ • Dec 17Kaneka Corporation to Report Q3, 2021 Results on Feb 09, 2021Kaneka Corporation announced that they will report Q3, 2021 results on Feb 09, 2021
Is New 90 Day High Low • Dec 17New 90-day high: €28.40The company is up 19% from its price of €23.80 on 18 September 2020. The German market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €11.62 per share.
Analyst Estimate Surprise Post Earnings • Nov 14Revenue beats expectationsRevenue exceeded analyst estimates by 1.4%. Over the next year, revenue is forecast to grow 1.1%, compared to a 3.6% growth forecast for the Chemicals industry in Germany.
Is New 90 Day High Low • Nov 12New 90-day high: €25.80The company is up 22% from its price of €21.20 on 14 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.41 per share.
Reported Earnings • Nov 11Second quarter 2021 earnings released: EPS JP¥31.26The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: JP¥140.1b (down 7.3% from 2Q 2020). Net income: JP¥2.04b (down 20% from 2Q 2020). Profit margin: 1.5% (down from 1.7% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Oct 12New 90-day high: €25.60The company is up 21% from its price of €21.20 on 14 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €9.76 per share.
Is New 90 Day High Low • Sep 18New 90-day high: €24.80The company is up 8.0% from its price of €23.00 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €10.11 per share.
お知らせ • Sep 13Kaneka Corporation to Report Q2, 2021 Results on Nov 10, 2020Kaneka Corporation announced that they will report Q2, 2021 results on Nov 10, 2020
お知らせ • Jun 28Kaneka Corporation to Report Q1, 2021 Results on Aug 12, 2020Kaneka Corporation announced that they will report Q1, 2021 results on Aug 12, 2020
